Rs401681 and rs402710 polymorphisms of CLPTM1L gene in cancerous and healthy lung tissues in patients with lung adenocarcinoma
More details
Hide details
Department of Clinical Pharmacology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland / Zakład Farmakologii Klinicznej, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
Department of Thoracic Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland / Katedra i Klinika Chirurgii Klatki Piersiowej, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
Department of Pathomorphology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland / Katedra i Zakład Patomorfologii, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
Department of Internal Medicine, Diabetology and Nephrology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland / Katedra Chorób Wewnętrznych, Diabetologii i Nefrologii, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
Department of Environmental Medicine and Epidemiology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Katowice, Poland / Katedra i Zakład Medycyny i Epidemiologii Środowiskowej, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach
Corresponding author
Joanna Żywiec   

Zakład Farmakologii Klinicznej, Wydział Nauk Medycznych w Zabrzu, Śląski Uniwersytet Medyczny w Katowicach, ul. 3 Maja 13-15, 41-800 Zabrze
Ann. Acad. Med. Siles. 2023;77:166–175
The search for factors influencing the survival of patients with lung cancer is still ongoing. It may potentially be a polymorphism of the cleft lip and palate transmembrane 1-like (CLPTM1L) gene, which is involved in the process of carcinogenesis. The aim of the study was to assess the distribution of genotypes and alleles of selected polymorphisms of the CLPTM1L gene – rs401681 and rs402710 – in cancerous and healthy lung tissue in patients with lung adenocarcinoma and their relationship with patient survival.

Material and methods:
The study included 133 patients with an average age of lung cancer diagnosis of 65 years, who had undergone lung adenocarcinoma surgery in the past. Genetic material – deoxyribonucleic acid (DNA) – was isolated from paraffin-protected specimens of cancerous and healthy lung tissue, and genotyping of CLPTM1L polymorphisms was performed. The obtained results were analyzed along with demographic data, history of smoking, family history of cancer, stage of the disease in the tumor, node, metastasis (TNM) classification, clinical stage of the cancer and the survival time of the patients.

The mean follow-up period was 44.5 months. The patients who died lived an average of 22.6 months from the time of cancer diagnosis. There were no significant differences between the distribution of genotypes or alleles in the cancerous and healthy tissues and their relationship with the survival of the patients. The age at the time of diagnosis of cancer, category N in the TNM classification and high clinical advancement of the cancer were the only factors influencing the survival of the patients.

No relationships between the polymorphic variability of rs401681 and rs402710 in cancerous and healthy lung tissue and the survival of patients were found.

Study was funded by the Medical University of Silesia, Katowice, Poland, grant no. KNW-1-005/N/8/K.
The authors declare that no competing interests exist.
Ferlay J., Soerjomataram I., Ervik M., Dikshit R., Eser S., Mathers C. et al. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase. No. 11. Lyon, France: International Agency for Research on Cancer 2013; [online] [accessed on 15 September 2023].
Allemani C., Weir H.K., Carreira H., Harewood R., Spika D., Wang X.S. et al. Global surveillance of cancer survival 1995–2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2). Lancet 2015; 385(9972): 977−1010, doi: 10.1016/S0140-6736(14)62038-9.
Thun M.J., Henley S.J., Burns D., Jemal A., Shanks T.G., Calle E.E. Lung cancer death rates in lifelong nonsmokers. J. Natl. Cancer Inst. 2006; 98(10): 691−699, doi: 10.1093/jnci/djj187.
Couraud S., Souquet P.J., Paris C., Dô P., Doubre H., Pichon E. et al. BioCAST/IFCT-1002: epidemiological and molecular features of lung cancer in never-smokers. Eur. Respir. J. 2015; 45(5): 1403–1414, doi: 10.1183/09031936.00097214.
Lebrett M.B., Crosbie E.J., Smith M.J., Woodward E.R., Evans D.G., Crosbie P.A.J. Targeting lung cancer screening to individuals at greatest risk: the role of genetic factors. J. Med. Genet. 2021; 58(4): 217−226, doi: 10.1136/jmedgenet-2020-107399.
Wang J., Liu Q., Yuan S., Xie W., Liu Y., Xiang Y. et al. Genetic predisposition to lung cancer: comprehensive literature integration, meta-analysis, and multiple evidence assessment of candidate-gene association studies. Sci. Rep. 2017; 7(1): 8371, doi: 10.1038/s41598-017-07737-0.
Zhang X., Sjöblom T. Targeting loss of heterozygosity: A novel paradigm for cancer therapy. Pharmaceuticals (Basel). 2021; 14(1): 57, doi: 10.3390/ph14010057.
Mendes-da-Silva P., Moreira A., Duro-da-Costa J., Matias D., Monteiro C. Frequent loss of heterozygosity on chromosome 5 in non-small cell lung carcinoma. Mol. Pathol. 2000; 53(4): 184−187, doi: 10.1136/mp.53.4.184.
Yoshino I., Osoegawa A., Yohena T., Kameyama T., Oki E., Oda S. et al. Loss of heterozygosity (LOH) in non-small cell lung cancer: difference between adenocarcinoma and squamous cell carcinoma. Respir. Med. 2005; 99(3): 308−312, doi: 10.1016/j.rmed.2004.08.008.
Liu C., Cui H., Gu D., Zhang M., Fang Y., Chen S. et al. Genetic polymorphisms and lung cancer risk: Evidence from meta-analyses and genome-wide association studies. Lung Cancer 2017; 113: 18−29, doi: 10.1016/j.lungcan.2017.08.026.
Xun X., Wang H., Yang H., Wang H., Wang B., Kang L. et al. CLPTM1L genetic polymorphisms and interaction with smoking and alcohol drinking in lung cancer risk: a case-control study in the Han population from northwest China. Medicine (Baltimore) 2014; 93(28): e289, doi: 10.1097/MD.0000000000000289.
Tian J., Wang Y., Dong Y., Chang J., Wu Y., Chang S. et al. Cumulative evidence for relationships between multiple variants in the TERT and CLPTM1L region and risk of cancer and non-cancer disease. Front. Oncol. 2022; 12: 946039, doi: 10.3389/fonc.2022.946039.
Yamamoto K., Okamoto A., Isonishi S., Ochiai K., Ohtake Y. A novel gene, CRR9, which was up-regulated in CDDP-resistant ovarian tumor cell line, was associated with apoptosis. Biochem. Biophys. Res. Commun. 2001; 280(4): 1148−1154, doi: 10.1006/bbrc.2001.4250.
Zhang R., Shen S., Wei Y., Zhu Y., Li Y., Chen J. et al. A large-scale genome-wide gene-gene interaction study of lung cancer susceptibility in Europeans with a trans-ethnic validation in Asians. J. Thorac. Oncol. 2022; 17(8): 974−990, doi: 10.1016/j.jtho.2022.04.011.
Lim W., Ridge C.A., Nicholson A.G., Mirsadraee S. The 8th lung cancer TNM classification and clinical staging system: review of the changes and clinical implications. Quant. Imaging Med. Surg. 2018; 8(7): 709−718, doi: 10.21037/qims.2018.08.02.
Hou Y., Xue F., Fu Y., Feng G., Wang R., Yuan H. CLPTM1L is a novel putative oncogene promoting tumorigenesis in oral squamous cell carcinoma. Cell Transplant. 2021; 30: 9636897211045970, doi: 10.1177/09636897211045970.
Zienolddiny S., Skaug V., Landvik N.E., Ryberg D., Phillips D.H., Houlston R. et al. The TERT-CLPTM1L lung cancer susceptibility variant associates with higher DNA adduct formation in the lung. Carcinogenesis 2009; 30(8): 1368−1371, doi: 10.1093/carcin/bgp131.
Ni Z., Chen Q., Lai Y., Wang Z., Sun L., Luo X. et al. Prognostic significance of CLPTM1L expression and its effects on migration and invasion of human lung cancer cells. Cancer Biomark. 2016; 16(3): 445−452, doi: 10.3233/CBM-160583.
James M.A., Wen W., Wang Y., Byers L.A., Heymach J.V., Coombes K.R. et al. Functional characterization of CLPTM1L as a lung cancer risk candidate gene in the 5p15.33 locus. PLoS One 2012; 7(6): e36116, doi: 10.1371/journal.pone.0036116.
Ni Z., Tao K., Chen G., Chen Q., Tang J., Luo X. et al. CLPTM1L is overexpressed in lung cancer and associated with apoptosis. PLoS One 2012; 7(12): e52598, doi: 10.1371/journal.pone.0052598.
Li H., Che J., Jiang M., Cui M., Feng G., Dong J. et al. CLPTM1L induces estrogen receptor β signaling-mediated radioresistance in non-small cell lung cancer cells. Cell Commun. Signal. 2020; 18(1): 152, doi: 10.1186/s12964-020-00571-4.
Li C., Yin Z., Wu W., Li X., Zhou B. Genetic variants in TERT-CLPTM1L genetic region associated with several types of cancer: a meta-analysis. Gene 2013; 526(2): 390−399, doi: 10.1016/j.gene.2013.05.003.
Yang Y.C., Fu W.P., Zhang J., Zhong L., Cai S.X., Sun C. rs401681 and rs402710 confer lung cancer susceptibility by regulating TERT expression instead of CLPTM1L in East Asian populations. Carcinogenesis 2018; 39(10): 1216−1221, doi: 10.1093/carcin/bgy084.
Zhao D.P., Yang C.L., Zhou X., Ding J.A., Jiang G.N. Association between CLPTM1L polymorphisms (rs402710 and rs401681) and lung cancer susceptibility: evidence from 27 case-control studies. Mol. Genet. Genomics 2014; 289(5): 1001−1012, doi: 10.1007/s00438-014-0868-7.
Zhang X.L., Zhang X.J., Zhang Y.M., Zhang Q., Cao C.X., Gu D.Y. et al. Decreased risk of developing lung cancer in subjects carrying the CLPTM1L rs401681 (G>A) polymorphism: evidence from a meta-analysis. Genet. Mol. Res. 2014; 13(1): 1373−1382, doi: 10.4238/2014.February.28.10.
Tang J., Hu C., Mei H., Peng L., Li H. CLPTM1L gene rs402710 (C > T) and rs401681 (C > T) polymorphisms associate with decreased cancer risk: a meta-analysis. Oncotarget 2017; 8(60): 102446−102457, doi: 10.18632/oncotarget.22268.
Chen X.F., Cai S., Chen Q.G., Ni Z.H., Tang J.H., Xu D.W. Multiple variants of TERT and CLPTM1L constitute risk factors for lung adenocarcinoma. Genet. Mol. Res. 2012; 11(1): 370–378, doi: 10.4238/2012.February.16.2.